Clinical Trial

Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
\- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-26.
Trial Details
NCT Number NCT07003451
Lead Sponsor Assiut University
Conditions Rheumatoid Arthritis, Interstitial Lung Disease
Enrollment 60 participants
Start Date 2025-10-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-28